Get access

Reply to: Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

Authors

  • Madison T. Gray MSc,

    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Search for more papers by this author
  • Douglas A. Gray PhD,

    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Search for more papers by this author
  • John M. Woulfe MD, PhD, FRCP(C)

    Corresponding author
    1. Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
    2. Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    3. Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    4. Department of Pathology & Laboratory Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
    • Correspondence to: John M. Woulfe, Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Box 926, 501 Smyth Road, Ottawa, Ontario, Canada, E-mail: jwoulfe@ottawahospital.on.ca

    Search for more papers by this author

  • Funding agencies: This study was supported by The Parkinson's Society of Canada and the Michael J. Fox Foundation

  • Relevant conflicts of interest/financial disclosures: DAG and JMW jointly hold a Rapid Response Innovation Award from the Michael J. Fox Foundation. JMW has received an honorarium from Teva Pharmaceutical for a presentation on PD.

  • Full financial disclosures and author roles may be found in the online version of this article.

No abstract is available for this article.

Ancillary